Uploaded October 2022 | Updated November 2026, 9 hours ago
Air date: Wednesday, October 19, 2022, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS}
William E. Paul Lecture
Dr. Germain received his Sc.B. and Sc.M. from Brown University in 1970 and his M.D. and Ph.D. from Harvard Medical School and Harvard University in 1976. From 1976 to 1982, he served as an instructor, assistant professor, and associate professor of pathology at Harvard Medical School. From 1982 to 1987, he worked as a senior investigator in the Laboratory of Immunology (LI). In 1987, he was appointed chief of the Lymphocyte Biology Section. In 1994, Dr. Germain was named deputy chief of LI. In 2006, he became director of the NIAID Program in Systems Immunology and Infectious Disease Modeling, which became the Laboratory of Systems Biology in 2011 and for which he serves as chief of the laboratory. He is also acting chief of LI and associate director of the Trans-NIH Center for Human Immunology, Inflammation, and Autoimmunity (CHI). Since receiving his doctoral degrees, he has led a laboratory investigating basic immunobiology. He and his colleagues have made key contributions to our understanding of MHC class II molecule structure–function relationships, the cell biology of antigen processing, and the molecular basis of T cell recognition.
The Lymphocyte Biology Section (LBS) has made numerous contributions to the understanding of the cell biology of antigen processing and presentation by MHC class I and especially class II molecules. It also has examined recognition of these ligands by T cells with a focus on the signaling mechanisms involved in ligand discrimination. Since the early 2000’s, the LBS has conducted analysis of immune cell behavior in vivo using methods of intravital 2-photon imaging that it helped pioneer, providing real-time, high-resolution visualization of immune-cell dynamics in situ. More recently, the LBS has developed novel, highly multiplex section and volume imaging methods (Histo-cytometry and Ce3D) that allow an unprecedented analysis of cell phenotype, signaling, function, and location in complex tissue settings. These various imaging technologies are being used with more conventional molecular and cellular immunological methods to 1) describe the dynamics of innate and adaptive immune cell movement in lymphoid and non-lymphoid tissue; 2) localize the sites and duration of the cell-cell interactions involved in the development of adaptive immune responses; 3) analyze how differences in these aspects of cell migration and interaction affect differentiation events and functional immunity; and 4) investigate the dynamic behavior and effector activities of innate and adaptive immune cells in non-lymphoid sites.
For more information go to oir.nih.gov/wals
Author: Ron Germain, M.D., Ph.D., NIAID, NIH
Permanent link: videocast.nih.gov/watch=46005
Air date: Wednesday, October 19, 2022, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS}
William E. Paul Lecture
Dr. Germain received his Sc.B. and Sc.M. from Brown University in 1970 and his M.D. and Ph.D. from Harvard Medical School and Harvard University in 1976. From 1976 to 1982, he served as an instructor, assistant professor, and associate professor of pathology at Harvard Medical School. From 1982 to 1987, he worked as a senior investigator in the Laboratory of Immunology (LI). In 1987, he was appointed chief of the Lymphocyte Biology Section. In 1994, Dr. Germain was named deputy chief of LI. In 2006, he became director of the NIAID Program in Systems Immunology and Infectious Disease Modeling, which became the Laboratory of Systems Biology in 2011 and for which he serves as chief of the laboratory. He is also acting chief of LI and associate director of the Trans-NIH Center for Human Immunology, Inflammation, and Autoimmunity (CHI). Since receiving his doctoral degrees, he has led a laboratory investigating basic immunobiology. He and his colleagues have made key contributions to our understanding of MHC class II molecule structure–function relationships, the cell biology of antigen processing, and the molecular basis of T cell recognition.
The Lymphocyte Biology Section (LBS) has made numerous contributions to the understanding of the cell biology of antigen processing and presentation by MHC class I and especially class II molecules. It also has examined recognition of these ligands by T cells with a focus on the signaling mechanisms involved in ligand discrimination. Since the early 2000’s, the LBS has conducted analysis of immune cell behavior in vivo using methods of intravital 2-photon imaging that it helped pioneer, providing real-time, high-resolution visualization of immune-cell dynamics in situ. More recently, the LBS has developed novel, highly multiplex section and volume imaging methods (Histo-cytometry and Ce3D) that allow an unprecedented analysis of cell phenotype, signaling, function, and location in complex tissue settings. These various imaging technologies are being used with more conventional molecular and cellular immunological methods to 1) describe the dynamics of innate and adaptive immune cell movement in lymphoid and non-lymphoid tissue; 2) localize the sites and duration of the cell-cell interactions involved in the development of adaptive immune responses; 3) analyze how differences in these aspects of cell migration and interaction affect differentiation events and functional immunity; and 4) investigate the dynamic behavior and effector activities of innate and adaptive immune cells in non-lymphoid sites.
For more information go to oir.nih.gov/wals
Author: Ron Germain, M.D., Ph.D., NIAID, NIH
Permanent link: videocast.nih.gov/watch=46005

![Not Your Father’s Heart Disease: The Herstory and the NHLBI WISE
The research of C. Noel Bairey Merz, MD, focuses on heart disease in women, preventive cardiology, coronary physiology/pathophysiology and advanced cardiac imaging, as well as alternative and complementary medicine approaches to heart disease. Cardiovascular disease (CVD) is the leading cause of death in the US and on the planet, yet up to 70% of patients undergoing invasive angiography do not have obstructive coronary artery disease (CAD), more common in women than in men, as described by US and multi-national consensus documents. Although CMD has been documented over several decades, variability in symptom and stress testing characteristics lead to the widely held notion that these patients were “low risk”, very often receiving no specific therapy and dismissal from sub-specialty care. Evidence from the WISE original multicenter cohort, documented a higher risk of adverse events (e.g. death, myocardial infarction [MI], stroke, or hospitalization for heart failure [HF] or angina) emerging after 4-years of follow-up, comparable to patients with obstructive CAD, and higher in African American women25. Others have confirmed these findings and extended them to men (~20%). We have documented that most of these patients have coronary endothelial dysfunction, extensive but non-obstructive coronary atherosclerosis by intravascular ultrasound (IVUS), CMD, and myocardial ischemia. CMD, ischemia on stress testing, and angina persisting at 1-yr follow-up, identify patients at higher risk for adverse outcomes, most frequently hospitalization for HF, with preserved left ventricular (LV) ejection fraction (EF), i.e. HFpEF. Estimates from ACC/NCDR and WISE databases, indicate there are at least 3-4 million women and 1-2 million men in the US alone with INOCA who incur health-care costs similar to many with obstructive CAD. CMD may result from changes in function and/or structure of the coronary microcirculation, and in the absence of upstream obstructive CAD, is poorly understood mechanistically. Termed ischemia with no obstructive CAD (INOCA) and myocardial infarction with no obstructive CAD (MINOCA), these syndromes are increasingly observed in women, as well as men. Pharmacologic probe trials support anti-atherosclerotic and anti-ischemic therapies, and our ongoing clinical trial (WARRIOR NCT03417388) is testing high intensity statin, maximally-tolerated angiotensin-converting-enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) and low dose aspirin in women with INOCA for reduction of major adverse CV events (MACE); results are expected in 2025.
For more information go to https://oir.nih.gov/wals Not Your Father’s Heart Disease: The Herstory and the NHLBI WISE](https://i.ytimg.com/vi/plNCOgIPTDA/mqdefault.jpg)

![Forging a New Future: Inclusion of People with Disabilities in Technology Research and Development
Air date: Wednesday, January 11, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
When technology is properly created and applied it can be of tremendous benefit to people with disabilities. People with disabilities along with their allies know better than any other how being involved in the planning from day one is critical to a successfully accessible product, regardless of how many years in the future it lies. Dr. Cooper will present on technologies and research that he and members of the team at the Human Engineering Research Laboratories are working on ranging from Apps, cushions, homes, robots, and wheelchairs. Dr. Cooper will also speak about innovative education programs to build research and development capacity among people with disabilities and veterans.
Dr. Rory Cooper is the founding director at the Human Engineering Research Laboratories, a VA Rehabilitation Research and Development Center of Excellence in partnership with Pitt. Also, he serves as co-director of the NSF Quality of Life Technology Engineering Research Center, a joint Pitt-Carnegie Mellon University venture.
For more information go to https://oir.nih.gov/wals
Author: Rory Cooper, Ph.D., University of Pittsburgh
Permanent link: https://videocast.nih.gov/watch=46052 Forging a New Future: Inclusion of People with Disabilities in Technology Research and Development](https://i.ytimg.com/vi/qOF6gNww1m0/mqdefault.jpg)



![Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme
Air date: Wednesday, February 1, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture [WALS]
See https://en.wikipedia.org/wiki/Helen_Blau
For more information go to https://oir.nih.gov/wals
Author: Helen Blau, Ph.D., Stanford Medicine
Permanent link: https://videocast.nih.gov/watch=46058 Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme](https://i.ytimg.com/vi/rPVoQesTplU/mqdefault.jpg)


![Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras
Air date: Wednesday, March 8, 2023, 2PM
Description: NIH Directors WALS Lecture [WALS]
Kevan Shokat is a chemist who discovers drugs against some of the most common drivers of human cancers. He is best known for targeting a mutation that drives more than 1 in 10 lung cancers, opening up a new arena of cancer treatment discovery. The target, K-Ras, is the most common driver of cancer, and was considered “undruggable” by most cancer researchers after 40 years of failed attempts to block its function. Dr. Shokat’s discovery of a K-Ras blocker broke through this decades-old barrier and threw open the doors to a new class of cancer treatments. Lecture summary: 1. To understand the chemical, biochemical and cellular challenges to identifying a drug to target K-Ras mutant tumors 2. To learn how to discover drugs which only target oncogenes in cancer cells while sparing signaling in the rest of the body using covalent chemistry. 3. To learn about new approaches for combination therapy in cancer including re-activation of the tumor suppressor p53 and engaging the immune cells to overcome resistance to targeted therapies.
https://cancer.ucsf.edu/people/shokat.kevan
For more information go to https://oir.nih.gov/wals
Author: Kevan Shokat, Ph.D., University of California, Berkeley
Permanent link: https://videocast.nih.gov/watch=46070 Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras](https://i.ytimg.com/vi/rtR3yl5U4yk/mqdefault.jpg)